Skip to main content

Michael Nolan

Interim Department Head

Terry Companion Vet Med Center 2552

Bio

Dr. Nolan graduated from State University of New York at Stony Brook, earned his DVM degree at Virginia-Maryland Regional College of Veterinary Medicine, and his PhD in Radiation and Cancer Biology from Colorado State University. He completed an internship at NYC Veterinary Specialists and a residency in radiation oncology at Colorado State University. He is a Diplomate of the American College of Veterinary Radiology (sub-specialty of Radiation Oncology). Clinically, Dr. Nolan has a special interest in emerging technologies and techniques in radiation oncology. His research is focused on normal tissue injury secondary to radiation therapy, and developing novel therapeutic strategies to maximize comfort in patients with cancer.

AFFILIATIONS

Member, Radiation Research Society
Member, American Society for Radiation Oncology (ASTRO)
Member, Veterinary Cancer Society
Member, American College of Veterinary Radiology
Member, Comparative Medicine Institute, NC State
Member, North Carolina Veterinary Medical Association
Associate Member, Duke Cancer Institute

CERTIFICATIONS

Diplomate, American College of Veterinary Radiology (Radiation Oncology)

Area(s) of Expertise

NEUROBIOLOGY, SPONTANEOUS ANIMAL DISEASE MODELS, VETERINARY CANCER CARE
Normal Tissue Radiobiology:
The fundamental aim of Dr. Nolan's research is to reduce discomfort and side effects in patients undergoing cancer treatment. In particular, the Nolan lab studies the complex molecular signaling pathways that are activated in patients experiencing radiotherapy-associated pain, and they are working hard to understand how pain signaling can influence tumor behavior. Such knowledge is critical to developing new therapies that will maximize both quality and quantity of life in pets and people with cancer.

Developmental Therapeutics:
Dr. Nolan is the lead investigator for a number of clinical trials in veterinary oncology. This allows for testing and development of novel cancer therapies.

Publications

View all publications